Alglucosidase alfa

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Glycogen Storage Disease Type II

Conditions

Glycogen Storage Disease Type II, Pompe Disease, Acid Maltase Deficiency Disease, Glycogenosis 2

Trial Timeline

Jan 1, 2003 → Oct 1, 2003

NCT ID

NCT00051935

About Alglucosidase alfa

Alglucosidase alfa is a phase 2 stage product being developed by Sanofi for Glycogen Storage Disease Type II. The current trial status is completed. This product is registered under clinical trial identifier NCT00051935. Target conditions include Glycogen Storage Disease Type II, Pompe Disease, Acid Maltase Deficiency Disease.

What happened to similar drugs?

3 of 7 similar drugs in Glycogen Storage Disease Type II were approved

Approved (3) Terminated (0) Active (4)

✅ALGLUCOSIDASE ALFA (MYOZYME)SanofiApproved

✅Avalglucosidase alfa (GZ402666)SanofiApproved

✅Avalglucosidase alfaSanofiApproved

🔄avalglucosidase alfaSanofiPhase 3

🔄Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 3

🔄Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3

🔄Oral prednisolone + Placebo for oral prednisoloneUltragenyx PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04676373	Approved	Completed	Mar 10, 2021	Jul 25, 2024	Pompe's Disease
NCT01710813	Pre-clinical	Completed	Mar 20, 2015	Apr 20, 2021	Pompe Disease
NCT01410890	Approved	Completed	Nov 3, 2014	Nov 20, 2020	Pompe Disease
NCT00566878	Pre-clinical	Completed	Mar 31, 2012	Feb 9, 2024	Glycogen Storage Disease
NCT01526785	Approved	Terminated	Mar 1, 2012	Dec 1, 2014	Pompe Disease
NCT01288027	Approved	Completed	Jun 1, 2011	Dec 1, 2013	Pompe Disease (Late-Onset)
NCT00486889	Approved	Completed	Aug 26, 2008	Nov 23, 2021	Pompe Disease
NCT00483379	Approved	Completed	May 1, 2007	Jul 1, 2010	Pompe Disease
NCT00455195	Approved	Completed	Mar 1, 2007	Nov 1, 2008	Pompe Disease (Late-Onset)
NCT00074919	Pre-clinical	Completed	Dec 1, 2003	Feb 1, 2007	Glycogen Storage Disease Type II
NCT00051935	Phase 2	Completed	Jan 1, 2003	Oct 1, 2003	Glycogen Storage Disease Type II

Competing Products

20 competing products in Glycogen Storage Disease Type II

See all competitors

Product	Company	Stage	Hype Score
mRNA-3745	Moderna	Phase 2	0
alglucosidase alfa	Sanofi	Pre-clinical	26
avalglucosidase alfa	Sanofi	Phase 3	44
Myozyme	Sanofi	Phase 2/3	38
Myozyme	Sanofi	Pre-clinical	26
Avalglucosidase Alfa	Sanofi	Phase 2	35
Myozyme	Sanofi	Phase 2/3	38
ALGLUCOSIDASE ALFA (MYOZYME)	Sanofi	Approved	43
Avalglucosidase alfa (GZ402666)	Sanofi	Approved	47
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)	Sanofi	Phase 3	40
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)	Sanofi	Phase 2	39
Avalglucosidase alfa	Sanofi	Approved	50
Myozyme	Sanofi	Phase 1/2	32
Alglucosidase alfa GZ419829	Sanofi	Pre-clinical	30
alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])	Sanofi	Pre-clinical	26
alglucosidase alfa	Sanofi	Pre-clinical	26
Cipaglucosidase alfa + Miglustat	Amicus Therapeutics	Phase 3	44
BEAM-301: Single dose of BEAM-301 administered by IV	Beam Therapeutics	Phase 1/2	33
Oral prednisolone + Placebo for oral prednisolone	Ultragenyx Pharmaceutical	Phase 3	34
UX053 + Antipyretic + H2 Blocker + H1 Blocker	Ultragenyx Pharmaceutical	Phase 1/2	18